Skip to content
2000
Volume 1, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Despite the evident success of antiretroviral therapy in recent years, many patients undergoing intense treatment still struggle to find a cure for their disease due to drug resistance or treatment failure. To solve this problem, new antiretroviral drug alternatives are required. The HIV-1 antiretroviral drug fostemsavir (GSK3684394, previously BMS-663068) is a first-in-class HIV-1 attachment inhibitor with a novel mechanism. After oral administration, fostemsavir gets converted into temsavir in the gastrointestinal lumen, which then attaches to the glycoprotein 120 surface subunit on HIV-1 and produces a conformational change that prevents it from adhering to CD4+ T cells of the host immune system, thereby preventing the virus from infecting other cells. Fostemsavir is indicated in heavily treated (HTE) patients with an ideal antiretroviral (ARV) regimen. The drug has shown significant tolerability, and no hepatic or renal dose adjustments were required. Fostemsavir can be used as an effective alternative in salvage therapy because of its favourable adverse effect profile and few drug interactions.

© 2023 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X255078231011111629
2023-01-01
2025-10-03

  • From This Site

    /content/journals/cis/10.2174/012210299X255078231011111629
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/1/1/CIS-1-E2210299X255078.html?itemId=/content/journals/cis/10.2174/012210299X255078231011111629&mimeType=html&fmt=ahah

References

  1. WHOHIV and AIDS.Available from:https://www.who.int/news-room/fact-sheets/detail/hiv-aids (accessed Nov. 11, 2022)
  2. HemelaarJ. ElangovanR. YunJ. Dickson-TettehL. FlemingerI. KirtleyS. WilliamsB. Gouws-WilliamsE. GhysP.D. AbimikuA.G. AgwaleS. ArchibaldC. AvidorB. BarbásM.G. Barre-SinoussiF. BarugahareB. BelabbesE.H. BertagnolioS. BirxD. BobkovA.F. BrandfulJ. BredellH. BrennanC.A. BrooksJ. BruckovaM. BuonaguroL. BuonaguroF. ButtòS. BuveA. CampbellM. CarrJ. CarreraA. CarrilloM.G. CelumC. ChaplinB. CharlesM. ChatzidimitriouD. ChenZ. ChijiwaK. CooperD. CunninghamP. DagnraA. de GascunC.F. Del AmoJ. DelgadoE. DietrichU. DwyerD. EllenbergerD. EnsoliB. EssexM. GaoF. FleuryH. FonjungoP.N. FoulongneV. GadkariD.A. GarcíaF. GarsiaR. Gershy-DametG.M. GlynnJ.R. GoodallR. GrossmanZ. Lindenmeyer-GuimarãesM. HahnB. HamersR.L. HamoudaO. HandemaR. HeX. HerbeckJ. HoD.D. HolguinA. HosseinipourM. HuntG. ItoM. Bel Hadj KacemM.A. KahleE. KaleebuP.K. KalishM. KamarulzamanA. KangC. KankiP. KaramovE. KarasiJ-C. KayitenkoreK. KelleherT. KitayapornD. KostrikisL.G. KuchererC. LaraC. LeitnerT. LiitsolaK. LingappaJ. LinkaM. Lorenzana de RiveraI. LukashovV. MaayanS. MayrL. McCutchanF. MedaN. MenuE. MhaluF. MlokaD. MokiliJ.L. MontesB. MorO. MorgadoM. MoshaF. MoussiA. MullinsJ. NajeraR. NasrM. NdembiN. NeilsonJ.R. NerurkarV.R. NeuhannF. NolteC. NovitskyV. NyambiP. OfnerM. PaladinF.J. PapaA. PapeJ. ParkinN. ParryC. PeetersM. PelletierA. Pérez-ÁlvarezL. PillayD. PintoA. QuangT.D. RademeyerC. RaikanikodaF. RayfieldM.A. ReynesJ-M. Rinke de WitT. RobbinsK.E. RollandM. RousseauC. Salazar-GonzalesJ. SalemH. SalminenM. SalomonH. SandstromP. SantiagoM.L. SarrA.D. SchroederB. SegondyM. SelhorstP. SempalaS. ServaisJ. ShaikA. ShaoY. SlimA. SoaresM.A. SongokE. StewartD. StokesJ. SubbaraoS. SutthentR. TakehisaJ. TanuriA. TeeK.K. ThapaK. ThomsonM. TranT. UrassaW. UshijimaH. van de PerreP. van der GroenG. van LaethemK. van OosterhoutJ. van SighemA. van WijngaerdenE. VandammeA-M. VercauterenJ. VidalN. WallaceL. WilliamsonC. WoldayD. XuJ. YangC. ZhangL. ZhangR. Global and regional molecular epidemiology of HIV-1, 1990–2015: A systematic review, global survey, and trend analysis.Lancet Infect. Dis.201919214315510.1016/S1473‑3099(18)30647‑930509777
     [Google Scholar]
  3. NIHWhat’s New in the Guidelines.Available from:https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines (accessed Nov. 11, 2022)
  4. GulickR.M. FlexnerC. Long-acting HIV drugs for treatment and prevention.Annu. Rev. Med.201970113715010.1146/annurev‑med‑041217‑01371730355266
     [Google Scholar]
  5. LiangG. ZhangZ. ZhouY. Fostemsavir: A novel multidrug-resistant HIV-1 infection therapy.2022Available from:https://scholar.archive.org/work/bt26camiqrcnjc6rnplndqcycy/access/wayback/http://www.clausiuspress.com/conferences/LNMLS/BLSME%202022/Y0824.pdf (Accessed: Nov. 11, 2022)
  6. BerrutiM. PincinoR. TaramassoL. Di BiagioA. Evaluating fostemsavir as a therapeutic option for patients with HIV.Expert Opin. Pharmacother.202122121539154510.1080/14656566.2021.193712034125644
     [Google Scholar]
  7. KozalM. AbergJ. PialouxG. CahnP. ThompsonM. MolinaJ.M. GrinsztejnB. DiazR. CastagnaA. KumarP. LatiffG. DeJesusE. GummelM. GartlandM. PierceA. AckermanP. LlamosoC. LatailladeM. Fostemsavir in adults with multidrug-resistant HIV-1 infection.N. Engl. J. Med.2020382131232124310.1056/NEJMoa190249332212519
     [Google Scholar]
  8. ViiV Healthcare and Medicine Patent Pool statement on voluntary licences in enabling access to fostemsavirAvailable from:https://viivhealthcare.com/hiv-news-and-media/news/company-statements/fostemsavir-voluntary-licences-statement/ (accessed Oct. 18, 2022)
  9. ViiV healthcare submits new drug application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options availableAvailable from:https://viivhealthcare.com/en-us/media-center/news/press-releases/2019/december/viiv-healthcare-submits-new-drug-application-to-the-fda-for-fost/ (accessed Nov. 10, 2022)
  10. ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIVAvailable from:https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2021/february/viiv-healthcare-receives-marketing-authorisation-for-rukobia/ (accessed Oct. 16, 2022)
  11. ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options availableAvailable from:https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2020/december/viiv-healthcare-announces-positive-chmp-opinion-for-rukobia/ (accessed Oct. 18, 2022)
  12. CraftB.M. BakerD.E. Fostemsavir.Hosp. Pharm.2021Jan10.1177/0018578720985433
     [Google Scholar]
  13. HiryakK. KorenD.E. Fostemsavir: A novel attachment inhibitor for patients with multidrug-resistant HIV-1 infection.Ann. Pharmacother.202155679279710.1177/106002802096242432964736
     [Google Scholar]
  14. MageeM. SlaterJ. ManninoF. AckermanP. LlamosoC. MooreK. Effect of renal and hepatic impairment on the pharmacokinetics of temsavir, the active moiety of fostemsavir.J. Clin. Pharmacol.202161793995310.1002/jcph.181033368327
     [Google Scholar]
  15. NIHAntiretroviral medication Fostemsavir (FTR, Rukobia).Available from:https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/fostemsavir (accessed Nov. 11, 2022)
  16. SevalN. FrankC. KozalM. Fostemsavir for the treatment of HIV.Expert Rev. Anti Infect. Ther.202119896196610.1080/14787210.2021.186580133331202
     [Google Scholar]
  17. MeanwellN.A. KrystalM.R. Nowicka-SansB. LangleyD.R. ConlonD.A. EastgateM.D. GraselaD.M. TimminsP. WangT. KadowJ.F. Inhibitors of HIV-1 attachment: The discovery and development of temsavir and its prodrug fostemsavir.J. Med. Chem.2018611628010.1021/acs.jmedchem.7b0133729271653
     [Google Scholar]
  18. ThompsonM. LalezariJ.P. KaplanR. PinedoY. PenaO.A.S. CahnP. StockD.A. JoshiS.R. HannaG.J. LatailladeM. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: Week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.Antivir. Ther.201722321522310.3851/IMP311227922453
     [Google Scholar]
  19. LatailladeM. Viral drug resistance through 48 Weeks, in a Phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir.J. Acquir. Immune. Defic. Syndr.201877329930710.1097/QAI.0000000000001602
     [Google Scholar]
  20. LalezariJ.P. LatiffG.H. BrinsonC. EchevarríaJ. Treviño-PérezS. BognerJ.R. ThompsonM. FourieJ. Sussmann PenaO.A. Mendo UrbinaF.C. MartinsM. DiaconescuI.G. StockD.A. JoshiS.R. HannaG.J. LatailladeM. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.Lancet HIV2015210e427e43710.1016/S2352‑3018(15)00177‑026423650
     [Google Scholar]
  21. AndersonS.J. MurrayM. CellaD. GrossbergR. HaginsD. TownerW. WangM. ClarkA. PierceA. LlamosoC. AckermanP. LatailladeM. Patient-reported outcomes in the phase III brighte trial of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals.Patient202215113114310.1007/s40271‑021‑00534‑y34180035
     [Google Scholar]
  22. LatailladeM. LalezariJ.P. KozalM. AbergJ.A. PialouxG. CahnP. ThompsonM. MolinaJ.M. MorenoS. GrinsztejnB. DiazR.S. CastagnaA. KumarP.N. LatiffG.H. De JesusE. WangM. ChabriaS. GartlandM. PierceA. AckermanP. LlamosoC. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: Week 96 results of the phase 3 BRIGHTE study.Lancet HIV2020711e740e75110.1016/S2352‑3018(20)30240‑X33128903
     [Google Scholar]
  23. ChenB. Molecular mechanism of HIV-1 entry.Trends Microbiol.2019271087889110.1016/j.tim.2019.06.00231262533
     [Google Scholar]
  24. German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’Human Immunodeficiency Virus (HIV).Transfus. Med. Hemother.201643320322210.1159/00044585227403093
     [Google Scholar]
  25. PuJ. WangQ. XuW. LuL. JiangS. Development of protein- and peptide-based HIV entry inhibitors targeting gp120 or gp41.Viruses201911870510.3390/v11080705
     [Google Scholar]
  26. SarkarA. Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer.Nat. Commun.20189111410.1038/s41467‑018‑04272‑y
     [Google Scholar]
  27. BrelotA. ChakrabartiL.A. CCR5 revisited: How mechanisms of HIV entry govern AIDS pathogenesis.J. Mol. Biol.2018430172557258910.1016/j.jmb.2018.06.02729932942
     [Google Scholar]
  28. GartlandM. CahnP. DeJesusE. DiazR.S. GrossbergR. KozalM. KumarP. MolinaJ.M. Mendo UrbinaF. WangM. DuF. ChabriaS. ClarkA. GarsideL. KrystalM. ManninoF. PierceA. AckermanP. LatailladeM. Week 96 genotypic and phenotypic results of the fostemsavir phase 3 BRIGHTE study in heavily treatment-experienced adults living with multidrug-resistant HIV-1.Antimicrob. Agents Chemother.2022666e01751-2110.1128/aac.01751‑2135502922
     [Google Scholar]
  29. NajjarA. NajjarA. KaramanR. Newly developed prodrugs and prodrugs in development; an insight of the recent years.Molecules202025788410.3390/molecules25040884
     [Google Scholar]
  30. GravattL.A.H. LeibrandC.R. PatelS. McRaeM. New drugs in the pipeline for the treatment of HIV: A review.Curr. Infect. Dis. Reports201719111910.1007/s11908‑017‑0601‑x
     [Google Scholar]
  31. NIHFostemsavir - Patient.Available from:https://clinicalinfo.hiv.gov/en/drugs/fostemsavir/patient (accessed Nov. 11, 2022)
  32. CahnP. FinkV. PattersonP. Fostemsavir.Curr. Opin. HIV AIDS201813434134510.1097/COH.000000000000046929771694
     [Google Scholar]
  33. NettlesR.E. SchürmannD. ZhuL. StonierM. HuangS.P. ChangI. ChienC. KrystalM. Wind-RotoloM. RayN. HannaG.J. BertzR. GraselaD. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.J. Infect. Dis.201220671002101110.1093/infdis/jis43222896665
     [Google Scholar]
  34. Highlights of prescribing information These highlights do not include all the information needed to use RUKOBIA safely and effectively. See full prescribing information for RUKOBIAAvailable from:https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Rukobia/pdf/RUKOBIA-PI-PIL.PDF (Accessed: Aug. 27, 2023)
  35. LatailladeM. AckermanP. SchoofsT. ClarkA. KozalM. Fostemsavir in heavily treatment-experienced individuals living with HIV-1: Insights from the phase 3 brighte study.J. AIDS HIV Treat.202132313610.33696/AIDS.3.019
     [Google Scholar]
  36. Fostemsavir tromethamine.Am. J. Health Syst. Pharm.202077231924192710.1093/ajhp/zxaa29432936234
     [Google Scholar]
  37. PrévostJ. Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir.bioRxiv2023202353718110.1101/2023.04.17.537181
     [Google Scholar]
  38. GartlandM. ZhouN. StewartE. PierceA. ClarkA. AckermanP. LlamosoC. LatailladeM. KrystalM. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.J. Antimicrob. Chemother.202176364865210.1093/jac/dkaa47433241285
     [Google Scholar]
  39. LaiY.T. Small molecule HIV-1 attachment inhibitors: Discovery, mode of action and structural basis of inhibition.Viruses202113584310.3390/v13050843
     [Google Scholar]
/content/journals/cis/10.2174/012210299X255078231011111629
Loading
Fostemsavir: A Novel CD4 Attachment Inhibitor for Heavily Treated HIV-1 Patient
Curr. Indian Sci. 1, E2210299X255078 (2023); https://doi.org/10.2174/012210299X255078231011111629
/content/journals/cis/10.2174/012210299X255078231011111629
/content/journals/cis/10.2174/012210299X255078231011111629
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Anti-retroviral treatment; Disease; Drug; Fostemsavir; HIV; HIV attachment inhibitor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test